Immix Biopharma, Inc.
IMMXImmix Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies.
Earnings
Next report
Aug 14, 2026 (In 2 weeks)EPS estimate-$0.17
Valuation & ratios
Competitors
By market cap
Profile
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of next-generation chimeric antigen receptor T-cell (CAR-T) therapies. The company's core value proposition centers on its proprietary N-GENIUS platform, which is designed to produce cell therapies with high transduction efficiency and low toxicity for treating light chain (AL) amyloidosis and other serious diseases.
Competitive position
Clinical-stage developer of the first and only autologous CAR-T therapy currently being developed specifically for light-chain (AL) amyloidosis.
GeographiesUnited States, Israel, Australia, European Union
Customer segmentsPatients, Hospitals
Business modelResearch and Development, IP Licensing
SuppliersContract Manufacturing Organizations (CMOs), Academic research centers, Specialized laboratory equipment suppliers, Raw material and API providers
CustomersSpecialized oncology and hematology centers, Clinical trial sites, Pharmaceutical distributors (future)
CountryUnited States of America
Listed2021
Employees17.0
CEOIlya Rachman
SectorHealthcare
IndustryBiotechnology
Websiteimmixbio.com
FilingsSEC EDGAR
Questions, answered.
- What is Immix Biopharma, Inc.'s market cap?
- Immix Biopharma, Inc. (IMMX) has a market capitalization of $618.6M and trades on NASDAQ.
- Who are Immix Biopharma, Inc.'s competitors?
- Immix Biopharma, Inc.'s key competitors include AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Immix Biopharma, Inc. partner with?
- Immix Biopharma, Inc.'s notable partners include Memorial Sloan Kettering Cancer Center, Hadasit Medical Research Services & Development, Ltd., BIRAD – Research and Development Company Ltd., and others.
- What subsidiaries does Immix Biopharma, Inc. have?
- Immix Biopharma, Inc.'s subsidiaries include Nexcella, Inc., Immix Biopharma Australia Pty Ltd..
- Where is Immix Biopharma, Inc. headquartered?
- Immix Biopharma, Inc. is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2021.